FDA Approves Merck & Gilead Combo, Forging a New Frontline for TNBC

RAHWAY, N.J. & FOSTER CITY, Calif. – June 25, 2026 – The U.S. Food and Drug Administration (FDA) today approved a transformative combination therapy from Merck and Gilead, heralding a new era for patients with a particularly aggressive form of breast cancer. The approval covers Merck’s blockbuster immunotherapy KEYTRUDA® (pembrolizumab) and its subcutaneous version, KEYTRUDA QLEX™, each to be used with Gilead’s antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy).

This regimen is now a first-line treatment option for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express the biomarker PD-L1 (CPS ≥10). The decision marks the first-ever approval of a PD-1 inhibitor combined with a Trop-2-directed ADC in this setting, establishing a new standard of care and offering significant hope to a patient population with historically limited and often ineffective initial treatment choices.

A New Standard Built on Superior Clinical Data

The FDA’s green light is anchored by the robust results of the Phase 3 KEYNOTE-D19/ASCENT-04 trial. The study demonstrated that the KEYTRUDA-Trodelvy combination significantly outperformed the existing standard of care, which paired KEYTRUDA with traditional chemotherapy. Patients receiving the novel combination saw their risk of disease progression or death reduced by a remarkable 35%.

Clinically, this translated into a median progression-free survival (PFS) of 11.2 months, a substantial improvement over the 7.8 months observed in the KEYTRUDA-plus-chemotherapy arm. Beyond simply delaying progression, the responses were more profound and durable. The objective response rate (ORR) climbed to 61% with the new combination, compared to 55% with chemotherapy. More impressively, the median duration of response stretched to 16.5 months, far surpassing the 9.2 months seen with the older regimen. This durability is critical in TNBC, where responses can often be fleeting.

“For people living with metastatic triple-negative breast cancer, the first treatment choice can be pivotal, as many patients may not have the opportunity to receive subsequent therapies,” said Dr. Sara Tolaney, a principal investigator on the study and Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. “These approvals are heartening news for patients and the clinical community, and I believe offer practice-changing first-line treatment options.”

The safety profile was consistent with the known effects of each drug, with no new or unexpected safety signals emerging. Critically, fewer patients had to stop treatment due to adverse events in the KEYTRUDA-Trodelvy arm (9%) compared to the chemotherapy arm, suggesting the combination is not only more effective but also more tolerable for many.

The Science of Synergy: Unleashing a Two-Pronged Attack

The strategic power of this new regimen lies in its dual-action mechanism, which creates a powerful synergy against cancer cells. KEYTRUDA is an immuno-oncology agent that blocks the PD-1 protein on immune cells, essentially “releasing the brakes” on the immune system and enabling it to recognize and attack tumors. However, its effectiveness can be limited if the tumor microenvironment is not conducive to an immune response.

This is where Trodelvy, a highly advanced ADC, comes into play. Often described as a “smart bomb,” it targets Trop-2, a protein overexpressed on the surface of most TNBC cells. The ADC binds to these cells and delivers a potent chemotherapy payload (SN-38) directly inside, killing the cancer cells while minimizing damage to healthy tissue. According to oncology experts, Trodelvy also creates a “bystander effect,” where the payload released from dying cancer cells can kill nearby tumor cells that may not even express Trop-2. This process inflames the tumor microenvironment, making it more visible and vulnerable to the reinvigorated immune system unleashed by KEYTRUDA.

“We now have new first-line treatment options that combine, for the first time, a PD-1 inhibitor with a Trop-2-directed ADC, and significantly reduce disease progression or death compared to KEYTRUDA plus chemotherapy,” said Dr. Gursel Aktan, vice president of global clinical development at Merck Research Laboratories. “Today’s approvals…represent a meaningful milestone for those living with advanced TNBC.”

Reshaping the Market and Patient Experience

This approval strategically repositions Merck and Gilead at the forefront of the increasingly competitive TNBC market. It directly challenges the long-standing paradigm of chemotherapy-based first-line treatment, offering a clearly superior alternative for the large segment of patients whose tumors are PD-L1 positive.

The timing is also significant, coming shortly after the approval of a rival TROP2 ADC, Datopotamab Deruxtecan, for a different subset of TNBC patients. This new KEYTRUDA-Trodelvy approval solidifies a dominant position for the partnership in the PD-L1 positive space, a key battleground in oncology.

Further enhancing its market position is the concurrent approval of KEYTRUDA QLEX, a subcutaneous formulation of the drug. Administered as a simple injection in just one to two minutes, it stands in stark contrast to the 30-minute intravenous infusion required for the standard formulation. This innovation promises to dramatically reduce the time patients spend in infusion centers, easing the treatment burden and offering greater flexibility. For healthcare systems, it can improve operational efficiency and free up valuable resources in busy oncology clinics.

A Lifeline for a High-Need Community

Perhaps the most profound impact of this approval will be felt by patients. TNBC is a formidable disease, accounting for 10-15% of all breast cancers. It disproportionately strikes younger women, often under 40, and is more prevalent in Black and Hispanic women. Its aggressive biology means it grows and spreads faster, with a higher risk of early recurrence and worse overall outcomes compared to other breast cancer types.

“Because so many patients may never receive subsequent lines of therapy, the ability to start with options like Trodelvy with or without KEYTRUDA or KEYTRUDA QLEX is critical,” said Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance. “We have sought additional alternatives to chemotherapy-containing regimens in the first-line metastatic setting since TNBC was classified as a disease more than 20 years ago. As such, these approvals represent meaningful progress for the families impacted by this disease.”

Ensuring broad patient access to this new standard of care will be crucial. In a move that will help streamline insurance coverage, the National Comprehensive Cancer Network® (NCCN®) has already updated its guidelines to include this combination as a Category 1 preferred option. Both Merck and Gilead have robust patient support programs in place, which will be essential in helping patients navigate financial and logistical barriers to accessing this life-extending therapy.